Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01938404

Octaplas Adult TTP Trial

Thrombotic Thrombocytopenic Purpura Clinical Trial

Official title:
Post-Marketing Requirement Study to Evaluate the Safety and Efficacy of Octaplas™ in Patients With Thrombotic Thrombocytopenic Purpura With Special Emphasis on Monitoring the Occurrence of Thromboembolic Events

Clinical Trial Summary

To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on the occurrence of thromboembolic events (TEEs).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01938404
Study type Observational
Source Octapharma
Contact
Status Terminated
Phase
Start date June 6, 2017
Completion date August 2, 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Recruiting NCT05785468 - A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
Completed NCT04074187 - A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Phase 2/Phase 3
Terminated NCT00953771 - Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) Phase 2
Recruiting NCT01257269 - Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Not yet recruiting NCT05568147 - Aspirin for Prophylaxis of TTP Phase 2/Phase 3
Recruiting NCT05468320 - Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Phase 3
Completed NCT00713193 - Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Phase 3
Completed NCT00426686 - ADAMTS13 in Thrombotic Thrombocytopenic Purpura N/A
Withdrawn NCT00251277 - Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura Phase 1/Phase 2
Recruiting NCT04588194 - Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia Phase 2
Active, not recruiting NCT03237819 - Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Phase 3
Completed NCT00907751 - Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Phase 2
Completed NCT03369314 - Observational Study of the Use of octaplasLG®.
Recruiting NCT04981028 - The ConNeCT Study: Neurological Complications of TTP
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Recruiting NCT05389007 - .German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
Withdrawn NCT02626663 - The Role of Microparticles as a Biomarker
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Terminated NCT00593229 - International Registry and Biorepository for TMA(Thrombotic Microangiopathy) N/A